Sanara MedTech Inc.

Listed Company

SMTICIK 0000714256NasdaqNon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesTexasFY ends Dec 31

Period

FY 2025

Revenue

$103.12M

Net Income

$-37.56M

Total Assets

$72.94M

Equity

$5.94M

Shares Out

9.16M

Op. Cash Flow

$6.79M

SMTI$25.33−7.93% · past yearDBEQ Basic

Daily closing prices

Business

Sanara MedTech is a medical technology company developing and commercializing surgical wound care and orthobiologic products for use in operating rooms and sterile environments. Its lead products include CellerateRX Surgical (hydrolyzed collagen powder for wound management), BIASURGE (sterile irrigation solution), BiFORM (bioactive moldable bone matrix), and ALLOCYTE Plus (viable bone matrix). The company operates as a single reportable segment focused on the U.S. surgical tissue repair market, selling through a network of surgical specialty distributors and field sales representatives credentialed to hospitals and surgical centers.

Summary from 10-K filed 2026-03-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Revenue	103	87	65	46	24
Cost of goods sold	8	8	8	6	2
Gross profit	96	79	57	39	22
Selling, general and administrative	79	72	57	46	28
Research and development	5	3	4	3	558,704
Depreciation and amortization	3	3	4	2	596,975
Change in fair value of earnout liabilities	—	−14,451	—	—	—
Asset impairment charges	2	—	—	—	—
Total operating expenses	88	77	61	52	29
Operating income	7	1	−4	−13	−7
Interest expense	−7	−3	−475,783	—	−711
Share of losses from equity method investments	−952,466	−90,007	—	−379,633	−616,927
Interest income	3,672	21,978	—	—	—
Gain on disposal of property and equipment	10,932	—	—	—	—
Total other income (expense)	−8	−3	−224,749	−1	−617,638
Net loss from continuing operations	−393,124	−2	—	—	—
Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3)	−37	−8	—	—	—
Net loss	−38	−10	−4	−8	−8
Net loss attributable to noncontrolling interest from continuing operations	−5,441	−3,224	—	—	—
Net loss attributable to noncontrolling interest from discontinued operations	—	−244,127	—	—	—
Less: Total net loss attributable to noncontrolling interest	−5,441	−247,351	−136,705	−154,831	−71,881
Net loss attributable to Sanara MedTech shareholders	−38	−10	−4	−8	−8
Continuing operations, basic	−0.05	−0.23	—	—	—
Continuing operations, diluted	−0.05	−0.23	—	—	—
Discontinued operations, basic	−4.31	−0.91	—	—	—
Discontinued operations, diluted	−4.31	−0.91	—	—	—
Net loss per share of common stock, basic	−4.36	−1.14	−0.52	−1	−1.08
Net loss per share of common stock, diluted	−4.36	−1.14	−0.52	−1	—
Weighted average number of common shares outstanding, basic	9	8	8	8	7
Weighted average number of common shares outstanding, diluted	9	8	8	8	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2022 2022-12-31
Cash	17	16	5	—	9
Inventory, net	4	3	5	—	4
Convertible loan receivable	—	1	—	—	—
Prepaid and other assets	948,620	1	608,411	—	1
Current assets related to discontinued operations (Note 3)	67,863	101,334	—	—	—
Total current assets	34	33	19	—	21
Intangible assets, net	19	23	45	—	32
Goodwill	4	4	4	—	4
Investment in equity securities	15	6	3	—	3
Right of use assets operating leases	2	1	2	2	806,402
Property and equipment, net	456,962	432,317	1	—	1
Long-term assets related to discontinued operations (Note 3)	—	20	—	—	—
Total long-term assets	39	55	55	—	40
Total assets	73	88	74	—	61
Accrued bonuses and commissions	12	10	8	—	8
Accrued royalties and expenses	3	2	2	—	2
Earnout liabilities current	235,001	—	1	—	1
Operating lease liabilities current	353,229	358,687	361,185	—	313,933
Current liabilities related to discontinued operations (Note 3)	1	1	—	—	—
Total current liabilities	19	15	14	—	13
Long-term debt	46	31	9	—	—
Earnout liabilities long-term	—	748,001	3	—	6
Operating lease liabilities long-term	2	1	2	—	505,291
Other long-term liabilities	548,125	1	2	—	—
Total long-term liabilities	48	34	16	—	7
Total liabilities	67	49	29	—	19
Commitments and contingencies (Note 10)	—	—	—	—	—
Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,946,913 issued and outstanding as of December 31, 2025 and 8,753,773 issued and outstanding as of December 31, 2024	8,948	8,754	8,535	—	8,300
Additional paid-in capital	81	77	73	—	65
Accumulated deficit	−75	−38	−28	—	−23
Total Sanara MedTech shareholders equity	6	39	45	—	42
Equity attributable to noncontrolling interest	−8,666	−491,611	−244,260	—	−107,555
Total shareholders equity	6	39	45	—	42
Total liabilities and shareholders equity	73	88	74	—	61

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	4	5	—	—	—
Asset impairment charges	28	—	—	—	—
Gain on disposal of property and equipment	−9,674	—	—	—	41
Credit loss expense	509,233	624,448	202,941	280,000	51,536
Inventory obsolescence	582,046	521,757	406,812	540,090	251,826
Share-based compensation	5	4	3	3	3
Noncash lease expense	525,372	547,297	342,972	263,518	174,955
Back-end fee	780,312	358,086	—	—	—
Paid-in-kind interest	2	838,965	—	—	—
Accretion of finance liabilities	148,179	210,931	98,926	—	—
Amortization and write-off of debt issuance costs	279,905	209,499	5,138	—	—
Change in fair value of earnout liabilities	—	−2	—	—	—
Accrued interest income	—	−21,978	—	—	—
Accounts receivable, net	−114,690	−5	−2	−2	−695,018
Accounts receivable related parties	40,566	−32,166	90,148	−18,761	−79,787
Inventory, net	−2	1	−2	−517,271	−1
Prepaid and other assets	123,515	−515,496	496,200	−159,592	−305,501
Accounts payable	813,999	−424,318	531,380	−301,966	166,903
Accounts payable related parties	−5,913	−46,891	43,768	−121,781	−67,772
Accrued royalties and expenses	292,195	574,189	−739,645	—	—
Accrued bonuses and commissions	2	3	−81,513	—	—
Operating lease liabilities	−526,905	−502,892	−252,366	−263,370	−176,012
Net cash provided by (used in) operating activities	7	−23,784	−3	−6	−5
Purchases of property and equipment	−5	−205,848	−265,246	−147,015	−171,867
Proceeds from disposal of property and equipment	60,000	—	650	1,549	—
Purchases of intangible assets	−23,452	−23,452	—	−600,000	−578,586
Investment in equity securities	−8	−5	—	−250,000	−5
Convertible loan receivable	—	−1	—	—	—
CarePICS Acquisition	−2	—	—	—	—
Net cash used in investing activities	−15	−7	−10	−4	−5
Loan proceeds, net of debt issuance costs of $228,183 in 2025 and $1,160,740 in 2024	12	29	10	—	—
Pay off line of credit	—	−10	—	—	−800,000
Pay off debt assumed in CarePICS Acquisition	−2	—	—	—	—
Equity offering net expenses	—	−75,000	911,371	—	29
Net settlement of equity-based awards	−546,994	−125,205	−135,794	−407,346	−442,525
Cash payment of finance and earnout liabilities	−937,000	−2	−822,795	—	—
Net cash provided by financing activities	9	17	10	−627,346	28
Net increase in cash	700,562	11	−4	−10	18
Interest	3	2	283,948	206	711
Taxes	48,792	40,586	—	—	—
Non-monetary exchange to acquire intangible assets	2	—	—	—	—
Conversion of note receivable into equity method investment	1	—	—	—	—
Earnout liability generated by CarePICS Acquisition	1	—	4	7	—
Right of use assets obtained in exchange for lease obligations	1	—	2	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Sanara MedTech Inc.'s CIK number?

Sanara MedTech Inc.'s SEC CIK number is 0000714256 (714256). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Sanara MedTech Inc.'s SEC filings?

All of Sanara MedTech Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Sanara MedTech Inc. last report earnings?

Sanara MedTech Inc. (SMTI) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022291). This is Sanara MedTech Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Sanara MedTech Inc.'s most recent earnings 8-K?

Sanara MedTech Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001493152-26-022291. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Sanara MedTech Inc.'s latest earnings 8-K →
Look up any company's CIK number →